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Glycosaminoglycan and proteoglycan inhibit the depolymeri-
zation of 2-microglobulin amyloid fibrils in vitro.
Background. Although several kinds of evidence suggest
that glycosaminoglycans (GAGs) and proteoglycans (PGs) may
contribute to the development of 2-microglobulin–related
(A2m) amyloidosis, the precise roles of these molecules for
the development of A2m amyloidosis are poorly understood.
Methods. We investigated the effects of GAGs and PGs on
the depolymerization of A2m amyloid fibrils at a neutral pH,
as well as on the formation of the fibrils at an acidic pH in vitro,
using fluorescence spectroscopy with thioflavin T and electron
microscopy.
Results. Depolymerization of A2m amyloid fibrils at pH
7.5 at 37C was inhibited dose-dependently by the presence of
some GAGs (heparin, dermatan sulfate, or heparan sulfate)
or PGs (biglycan, decorin, or keratan sulfate proteoglycan).
Electron microscopy revealed that a significant amount of A2m
amyloid fibrils remained in the reaction mixture with some
lateral aggregation. Second, when monomeric 2m was incu-
bated with aggrecan, biglycan, decorin, or heparin at pH 2.5
at 37C for up to 21 days, the thioflavin T fluorescence increased
depending on dose and time. Electron microscopy revealed the
formation of rigid and straight fibrils similar to A2m amyloid
fibrils in 2m incubated with biglycan for 21 days.
Conclusion. These results suggest that some GAGs and PGs
could enhance the deposition of A2m amyloid fibrils in vivo,
possibly by binding directly to the surface of the fibrils and stabiliz-
ing the conformation of 2m in the fibrils, as well as by acting as
a scaffold for the polymerization of 2m into the fibrils.
2-Microglobulin–related (A2m) amyloidosis is a com-
mon and serious complication in patients on long-term
hemodialysis [1]. Carpal tunnel syndrome and destruc-
tive arthropathy associated with cystic bone lesions are
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the major clinical manifestations of A2m amyloidosis
[2, 3]. Intact 2m is a major structural component of A2m
amyloid fibrils [4–7]. The mechanism of the deposition
of these A2m amyloid fibrils is still unknown. Although
the retention of 2m in the plasma appears to be prereq-
uisite, other factors, such as the age of the patient, the
duration of dialysis, and the type of dialysis membrane
used, may also be involved [8–10].
We and other groups have proposed that a nucleation-
dependent polymerization model could explain the gen-
eral mechanisms of amyloid fibril formation in vitro, in
various types of human as well as murine amyloidosis
[11–16]. This model consists of two phases (i.e., nucleation
and extension). Nucleus formation requires a series of
association steps of monomers, which are thermodynami-
cally unfavorable, representing the rate-limiting step in
amyloid fibril formation in vitro. Once the nucleus (n-mer)
has been formed, further addition of monomers to the
nucleus becomes thermodynamically favorable, resulting
in rapid extension of amyloid fibrils in vitro [11, 13, 15].
This model has recently been evidenced in vivo by the fact
that apolipoprotein A II–related (AApoAII) and amyloid
protein A (AA) amyloidosis are markedly accelerated
when the animals are given an intravenous injection or
oral administration of AApoAII and AA amyloid fibrils,
respectively [17, 18]. The extension of A2m amyloid
fibrils, as well as the formation of the fibrils from 2m,
is greatly dependent on the pH of the reaction mixture,
with the optimum pH around 2.0 to 3.0 [15, 16]. On the
other hand, we have demonstrated that A2m amyloid
fibrils readily depolymerize into monomeric 2m at a
neutral to basic pH [19]. Using circular dichroism and
nuclear magnetic resonance spectroscopy, Kad et al [16],
Yamaguchi et al [19], and Hoshino et al [20] have re-
vealed a reversible change in the conformation of 2m
in the pH-dependent cycle of the polymerization and
depolymerization of A2m amyloid fibrils. At pH 2.5,
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where the extension of A2m amyloid fibrils is optimum,
2m loses much of the secondary and tertiary structures
observed at pH 7.5 [16, 19]. Although this amyloidogenic
intermediate is significantly populated at a physiologic
pH [21], the unphysiologic conditions at an acidic pH may
be quite efficient and reproducible to observe the forma-
tion and extension of A2m amyloid fibrils in vitro. Once
incorporated into A2m amyloid fibrils at pH 2.5, 2m
becomes highly rich in -sheet structure and obtains
the secondary and tertiary structures strikingly different
from monomeric 2m at both pH 7.5 and 2.5 [20]. Finally,
soon after the depolymerization from A2m amyloid fi-
brils at pH 7.5, 2m refolds to the native conformation
rich in -sheet structure [19].
A2m amyloid deposits contain many amyloid-associ-
ated molecules [e.g., glycosaminoglycans (GAGs), apo-
lipoprotein E (apoE), serum amyloid P component,
2-macroglobulin, and other plasma proteinase inhibi-
tors] [22, 23]. In A2m amyloid deposits, GAGs such as
heparan sulfate and chondroitin sulfate, as well as proteo-
glycans (PGs) such as chondroitin sulfate PG (CSPG) are
constantly increased [22, 24–26]. Furthermore, the earli-
est deposition of A2m amyloid is observed in the carti-
lage tissue [27, 28], highly rich in PGs such as aggrecan,
biglycan, decorin, and lumican [29–31]. Decorin is also
the constituent of the tendinous tissue (e.g., the carpal
tunnel) [32]. Thus, in order to understand the molecular
pathogenesis of A2m amyloidosis, it is essential to eluci-
date the roles of these molecules for the development
of A2m amyloidosis.
Recently, we demonstrated that apoE forms a stable
complex with A2m amyloid fibrils and inhibits the depo-
lymerization of A2m amyloid fibrils at a neutral pH
[19]. We proposed a model that apoE could enhance the
deposition of amyloid fibrils in vivo, possibly by binding
directly to the surface of the fibrils and stabilizing the
conformation of 2m in the fibrils. The roles of PGs and
their constituent GAGs for amyloid fibril formation in
vitro have been extensively studied in various types of
human as well as murine amyloidosis. It was reported
that heparan sulfate and the specific heparan sulfate pro-
teoglycan (HSPG), perlecan, can associate with serum
amyloid A (apoSAA), the precursor of inflammation-
associated AA amyloid [33], increase the-sheet content
of mouse apoSAA2 [34], and are closely implicated in
the initial stages of AA amyloidosis [35]. Perlecan was
found to enhance islet amyloid polypeptide (amylin) fi-
bril (AIAPP) formation, with the majority of these effects
attributed to the heparan sulfate chains of perlecan [36].
McLaurin et al [37] demonstrated that various GAGs
accelerate the -sheet transition of amyloid -peptide
(A) and the formation of well-defined -amyloid fibrils,
with chondroitin sulfate producing the most pronounced
effects. Castillo et al [38] reported that perlecan binds
to A, accelerates -amyloid fibril formation, and main-
tains -amyloid fibril stability. However, the roles of PGs
and GAGs in the polymerization and depolymerization
of A2m amyloid fibrils in vitro remain unclear.
In this paper, we investigated the roles of GAGs and
PGs in the depolymerization of A2m amyloid fibrils at
a neutral pH, as well as in the formation of the fibrils
at an acidic pH, using fluorescence spectroscopy with
thioflavin T and electron microscopic study.
METHODS
2m, GAGs, and PGs
Human recombinant 2m (r-2m) (Oriental Yeast,
Tokyo, Japan) was dissolved in 100 mmol/L NaCl at
concentrations of 300 to 450mol/L and stored at –80C.
Hyaluronic acid (182-19) was obtained from Nacalai
Tesque, Inc. (Kyoto, Japan). Chondroitin-4-sulfate (CS-A;
C8529), chondroitin-6-sulfate (CS-C; C4384), dermatan
sulfate (C3788), heparan sulfate (H9902), keratan sulfate
(K3001), heparin (low molecular weight, average molecular
weight, approximately 6000; H1636), aggrecan (A1960),
biglycan (B8041), decorin (D8428), HSPG (H4777), and
keratan sulfate proteoglycan (KSPG; K3009) were ob-
tained from Sigma Chemical Co. (St. Louis, MO, USA).
All GAGs and PGs were dissolved in 100 mmol/L NaCl
at concentrations of 10 and 1.0 mg/mL, respectively, and
stored at –20C.
Fluorescence spectroscopy and electron microscopy
All studies were performed as described elsewhere [15]
on a Hitachi F-3010 fluorescence spectrophotometer and
a Hitachi H-7000 electron microscope (Tokyo, Japan).
Optimum fluorescence measurements of A2m amyloid
fibrils were obtained at the excitation and emission wave-
lengths of 455 and 485 nm, respectively, with the reaction
mixture containing 5 mol/L thioflavin T (Wako Pure
Chemical Industries, Ltd., Osaka, Japan) and 50 mmol/L
glycine-NaOH buffer, pH 8.5 [15]. From each reaction
tube, 5 L aliquots in triplicate were subjected to fluo-
rescence spectroscopy and the mean of the three mea-
surements determined.
Depolymerization assay
Unmodified A2m amyloid fibrils composed solely of
r-2m were formed by the repeated extension reaction
with r-2m and the S0 seeds purified from synovial tis-
sues, excised surgically from patients suffering from
A2m amyloidosis [39]. The algorithmic protocol was
repeated 12 times, and the resulting F12 fibrils were
finally obtained from S11 seeds.
F12 fibrils were centrifuged at 18,500  g for 2 hours
at 4C. The pellets were washed and resuspended in ice-
cold 100 mmol/L NaCl. The reaction mixture was pre-
pared in oil-free polymerase chain reaction (PCR) tubes
(size, 0.5 mL; code number, 9046; Takara Shuzo Co.,
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Ltd., Otsu, Japan) on ice and contained 150 g/mL F12
fibrils, 50 mmol/L phosphate buffer, pH 7.5, 100 mmol/L
NaCl, and 0 to 1000 g/mL GAGs or 0 to 300 g/mL
PGs in a total volume of 30L. In some experiments, 150
g/mL heparan-stabilized fibrils or 225 g/mL decorin-
stabilized fibrils vide infra were added instead of F12
fibrils. The reaction tubes were transferred into a DNA
thermal cycler (PJ480; Perkin Elmer Cetus, Emeryville,
CA, USA) set at 37C. After a 24-hour incubation with-
out agitation, the reaction was stopped by placing the
tubes on ice.
Heparan- and decorin-stabilized A2m amyloid fibrils
were formed by the depolymerization reaction of the
fibrils at pH 7.5. The reaction mixture contained 150
g/mL F12 fibrils, 50 mmol/L phosphate buffer, pH 7.5,
100 mmol/L NaCl, and 300 g/mL of heparan or decorin.
After a 24-hour incubation at 37C, A2m amyloid fibrils
remaining in the mixture were collected by centrifuga-
tion at 18,500  g for 2 hours at 4C, washed, and resus-
pended in ice-cold 100 mmol/L NaCl. They were then
sonicated on ice with 10 intermittent pulses (pulse 0.6
second, interval 0.4 second, output level 2) using an ultra-
sonic disruptor (UD-201; Tomy, Tokyo, Japan) equipped
with a microtip (TP-030: Tomy), and stored at 4C.
Formation of A2m amyloid fibrils from monomeric2m
The stock solution of 2m was first centrifuged with
30,000 nominal molecular weight limit filter unit devices
(Biomax-30 high-flux, UFC3BTK25; Millipore Corpora-
tion, Bedford, MA, USA) at 5000  g for 20 minutes
at 4C. The reaction mixture was prepared on ice and
contained 50 mol/L r-2m, 50 mmol/L citrate buffer,
pH 2.5, 100 mmol/L NaCl, and 0 to 100 g/mL of PGs
or heparan. After brief vortexing of the mixture, 30 L
aliquots were put into PCR tubes. The reaction tubes
were then transferred into an incubator set at 37C. After
a 0- to 21-day incubation without agitation, the reaction
was stopped by placing the tubes on ice.
Other analytic procedures
Protein concentrations of r-2m and A2m amyloid
fibrils were determined with a commercial bicinchoninic
acid (BCA) protein assay reagents (Pierce, Rockford, IL,
USA). r-2m in phosphate-buffered saline (PBS) (0.5 mg
protein/mL) was used as the standard. One-way analysis
of variance, post hoc test by Scheffe was used for statisti-
cal analysis.
RESULTS
Effect of GAGs and PGs on the depolymerization of
A2m amyloid fibrils at a neutral pH
The thioflavin T fluorescence of F12 fibrils incubated
at pH 7.5 at 37C decreased immediately after the initia-
tion of the reaction [19]. At 24 hours, the fluorescence
of F12 fibrils was 5% to 6% of the initial fluorescence
(Figs. 1 and 2). The depolymerization of F12 fibrils was
inhibited depending on the dose of heparan, dermatan
sulfate or heparan sulfate (Fig. 1). The fluorescence of
F12 fibrils incubated with 1000 g/mL of heparan, der-
matan sulfate or heparan sulfate for 24 hours was about
16%, 10%, and 10% of the initial fluorescence, respec-
tively. Hyaluronic acid, CS-A, CS-C, and keratin sulfate
exhibited little or no inhibitory effect on the depolymeri-
zation of F12 fibrils.
The depolymerization of F12 fibrils was also inhibited
depending on the dose of all PGs examined, especially
by the presence of biglycan, decorin and KSPG (Fig. 2).
When F12 fibrils were incubated with 300g/mL of bigly-
can, decorin, KSPG, or HSPG for 24 hours, the fluores-
cence of F12 fibrils was about 40%, 32%, 42%, and 20%
of the initial fluorescence, respectively.
Electron microscopic study revealed that most of the
F12 fibrils in the reaction mixture depolymerized at 24
hours when incubated alone (Fig. 3A). On the other hand,
when F12 fibrils were incubated with heparan or decorin,
a significant amount of them remained in the reaction
mixture at 24 hours (Fig. 3B, heparan; and C, decorin).
The fibrils became shorter and laterally aggregated as com-
pared to the fibrils before depolymerization. The fluores-
cence of heparan- or decorin-stabilized fibrils was as high
as about 80% of the initial fluorescence in both cases
when incubated at pH 7.5 at 37C for 24 hours (Fig. 4).
Effect of PGs and heparan on the fibrillar assembly of
r-2m at an acidic pH
When monomeric 2m was incubated alone at pH 2.5
for up to 21 days, only a slight increase in the thioflavin
T fluorescence was observed (Fig. 5). Although few ag-
gregates with distinct morphology were observed at 24
hours (Fig. 6A), thin, short, curvilinear fibrils (so-called
“protofibrils”) were observed at 21 days (Fig. 6B). By
contrast, when monomeric 2m was incubated with ag-
grecan, biglycan, decorin, or heparan at pH 2.5 for up to
21 days, the thioflavin T fluorescence increased depending
on the time and dose (Fig. 5). Electron microscopy re-
vealed that fine granular aggregates with a few fine fila-
ments were observed in the reaction mixture at 24 hours
(Fig. 6C, biglycan; E, decorin; and G, heparan). Rigid
and straight fibrils similar to F12 fibrils were observed
in the mixture of monomeric 2m incubated with bi-
glycan for 21 days (Fig. 6D). These fibrils assumed the
nonbranched, helical filament structure of approximately
10 nm in width and exhibited a helical periodicity of
approximately 150 nm. When 2m was incubated with
decorin or heparan for 21 days, so-called “protofibrils”
were observed in the mixture (Fig. 6F, decorin; and H,
heparan). When 2m was incubated with aggrecan for
21 days, fine granular aggregates with a few straight
fibrils were observed (data not shown). When 2m was
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Fig. 1. Effect of glycosaminoglycans (GAGs) on the depolymerization of 2-microglobulin-related (A2m) amyloid fibrils at a neutral pH. The
reaction mixture containing 150 g/mL F12 fibrils, 50 mmol/L phosphate buffer, pH 7.5, 100 mmol/L NaCl, and 0 to 1000 g/mL GAGs was
incubated at 37C for 24 hours and analyzed by fluorescence spectroscopy. Each column represents the average of three independent experiments.
The error bars indicate standard deviations. *P  0.05; # P  0.01 versus control group (one-way analysis of variance, post hoc test by Scheffe).
Abbreviations are: HA, hyaluronic acid; CS-A, chondroitin-4-sulfate; CS-C; condroitin-6-sulfate; DS, dermatan sulfate; KS, keratan sulfate; HS,
heparan sulfate; and ThT, thioflavin T.
Fig. 2. Effect of proteoglycans (PGs) on the
depolymerization of 2-microglobulin-related
(A2m) amyloid fibrils at a neutral pH. The
reaction mixture containing 150 g/mL F12
fibrils, 50 mmol/L phosphate buffer, pH 7.5,
100 mmol/L NaCl, and 0 to 300 g/mL PGs
was incubated at 37C for 24 hours and ana-
lyzed by fluorescence spectroscopy. Each col-
umn represents the average of three indepen-
dent experiments. The error bars indicate
standard deviations. *P  0.05; #P  0.01 ver-
sus control group (one-way analysis of vari-
ance, post hoc test by Scheffe). Abbreviations
are: KSPG, keratan sulfate proteoglycan;
HSPG, heparan sulfate proteoglycan; and
ThT, thioflavin T.
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Fig. 3. Electron micrographs of depolymer-
ized 2-microglobulin-related (A2m) amy-
loid fibrils. The reaction mixture containing
150 g/mL F12 fibrils, 50 mmol/L phosphate
buffer, pH 7.5, 100 mM NaCl, and 0 (A) or 1000
g/mL heparan (B) or 300 g/mL decorin (C)
was incubated at 37C for 24 hours. Scale bars
250 nm.
Fig. 4. Depolymerization of heparan- and decorin-stabilized fibrils at
a neutral pH. The reaction mixture containing 150 g/mL heparan-
stabilized fibrils or 225 g/mL decorin-stabilized fibrils, 50 mmol/L
phosphate buffer, pH 7.5, and 100 mmol/L NaCl was incubated at 37C
for 24 hours and analyzed by fluorescence spectroscopy. Each column
represents the average of three independent experiments. The error
bars indicate standard deviations. ThT is thioflavin T.
incubated with aggrecan, biglycan, decorin, or heparan
at pH 7.5 for up to 21 days, no increase in the thioflavin
T fluorescence was observed (data not shown).
DISCUSSION
GAGs and PGs as stabilizers of A2m amyloid fibrils
Among all GAGs examined, heparan exhibited a
strong inhibitory effect on the depolymerization of the
fibrils when compared based on the weight concentration
(Fig. 1). In addition, dermatan sulfate and heparan sul-
fate also exhibited a significant inhibitory effect. This
inhibitory effect may roughly be correlated with the de-
gree of sulfation (i.e., the more sulfated, thus the more
negatively charged, the higher the inhibitory effect of
GAGs on the depolymerization). As suggested by the
interactions of GAGs and apoSAA [33], A [37, 40], or
2m [41], the ability of GAGs to stabilize A2m amyloid
fibrils may be correlated with the binding affinity of
GAGs to the specific residues of 2m in the fibrils. Fur-
ther studies are essential to elucidate the molecular
mechanisms of GAGs to stabilize A2m amyloid fibrils.
Among the PGs examined, biglycan, decorin, and KSPG
exhibited distinct stabilizing ability when compared
based on the weight concentration (Fig. 2). Interestingly,
these three PGs belong to the small leucine-rich PGs
(SLRPs) that have a similar structural motif, leucine-rich
repeat in the core protein [42, 43]. The core protein of
biglycan and decorin has been shown to bind to collagen
[32, 44], transforming growth factor- (TGF-) [45], and
the complement C1q [46, 47]. In cooperation with GAG
chains, the specific domain(s) of the core protein, highly
conserved among SLRPs might contribute to the stabili-
zation of A2m fibrils.
The above-described data suggest that some GAGs
and PGs could enhance the deposition of A2m amyloid
fibrils in vivo, possibly by binding directly to the surface
of the fibrils and stabilizing the conformation of 2m in
the fibrils, as well as by laterally aggregating the fibrils,
thus protecting them from the proteolysis in vivo [48].
GAGs and PGs as a scaffold for the polymerization of
A2m amyloid fibrils
In this section, we discuss two models for the thermo-
dynamically unfavorable nucleus formation from 2m
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Fig. 5. Effect of proteoglycans (PGs) and
heparan on the kinetics of fibrillar assembly
of monomeric recombinant 2-microglobulin
(r-2m) at an acidic pH. The reaction mixture
containing 50mol/L r-2m, 50 mmol/L citrate
buffer, pH 2.5, 100 mmol/L NaCl, and 0 (),
10 (), 30 (), or 100 () g/mL of PGs or
heparan was incubated at 37C for the indi-
cated times and analyzed by fluorescence spec-
troscopy. Each symbol represents the average
of two or three independent experiments. The
error bars indicate standard deviations.
in vitro. In the first model, 2m molecules would self-
assemble into the minimal nucleus simultaneously with
the cooperative change in their conformation. When 2m
is incubated at an acidic pH without agitation, short,
curvilinear “protofibrils” are formed instead of rigid and
straight fibrils similar to ex vivo A2m fibrils (Fig. 6B)
[15, 16]. Although we cannot rule out the possibility that
“protofibrils” may be units of mature amyloid fibrils,
hence, they would assemble further, they could alterna-
tively represent dead end products [15, 16]. Recently,
Kad et al [16] demonstrated that at an acidic pH and
low ionic strength with extensive agitation, rigid and
straight fibrils are formed from2m and the process could
be explained by a nucleation-dependent polymerization
model.
In the second model, the nucleus formation from 2m
molecules would be catalyzed by many kinds of biologic
molecules, including GAGs and PGs [36, 37, 49, 50].
Aggrecan, biglycan, decorin, and heparan accelerated
the fibrillar assembly of 2m at pH 2.5 (Figs. 5 and 6).
Interestingly, biglycan induced the formation of rigid
and straight fibrils, while decorin and heparan induced
the formation of “protofibrils.” Decorin, biglycan, and
aggrecan have 1, 2, and more than 100 GAG chains
per molecule, respectively [29]. Moreover, decorin and
biglycan belong to SLRPs [42, 43]. The specific confor-
mation of PGs achieved by both the core protein and
the GAG chains might be essential to catalyze the forma-
tion of rigid and straight fibrils in vitro.
Molecular environment of A2m amyloid
deposition in vivo
Various types of GAGs and PGs, especially heparan
sulfate and HSPG perlecan, have been identified in many
types of human and murine amyloidosis, including A2m,
AA, AIAPP, and A, and implicated in the development
of them [22, 24–26, 33–38, 41]. Even though heparan
sulfate and perlecan are ubiquitously synthesized in vivo
as a representative component of the basement mem-
brane and other extracellular matrices, the predominant
sites of amyloid deposition in vivo are different from
each other (i.e., A2m amyloid to be deposited in the
cartilaginous and tendinous tissues [2, 3, 27, 28], AA
amyloid to be deposited in the spleen and kidneys [35],
and AIAPP amyloid to be deposited in the islets of
Langerhans) [36]. Although the present study may partly
explain why A2m amyloid deposition takes place pre-
dominantly in the cartilaginous and tendinous tissues,
which are both rich in biglycan and decorin [30–32], there
have to be more specific reasons for the predominant
deposition in them. Further studies are essential to eluci-
date the mechanisms of tissue-specific deposition of
A2m amyloidosis.
We recently found that both uremic and normal se-
rums inhibit the depolymerization of A2m amyloid fi-
brils at a neutral pH in a concentration-dependent man-
ner, but the effects of both serums are not significantly
different from each other (unpublished observation).
Clinically, it is well known that the development of A2m
amyloidosis is not necessarily correlated with the plasma
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Fig. 6. Electron micrographs of fibrillar and
nonfibrillar aggregates of recombinant 2-micro-
globulin (r-2m) incubated with proteoglycans
(PGs) or heparan at an acidic pH. The reaction
mixture containing 50mol/L r-2m, 50 mmol/L
citrate buffer, pH 2.5, 100 mmol/L NaCl, and 0
(A and B) or 100 g/mL biglycan (C and D),
100 g/mL decorin (E and F), or 100 g/mL
heparan (G and H) was incubated at 37C for
24 hours (A, C, E, and G) or 21 days (B, D, F,
and H). Scale bars  250 nm.
2m concentration [51]. Alternatively, the age of the
patient may be involved in the development of A2m
amyloidosis (i.e., the older the patient, the shorter the
duration of hemodialysis before the manifestation of clini-
cal symptoms) [9]. One possible explanation for these
findings may be that age-related and uremia-dependent
changes in the molecular composition of the cartilage
and other connective tissues in the patient, including
some PGs [52–55], could provide a suitable molecular
environment or “scaffold” for the development of A2m
amyloidosis.
Heparan is widely used for hemodialysis as an anti-
coagulant. Although no significant difference in the prev-
alence of A2m amyloidosis was found between con-
tinuous ambulatory peritoneal dialysis patients and
hemodialysis patients carefully matched for time on dial-
ysis and age at the onset of dialysis [56], the present
study may suggest that heparan could exert a subtle
effect for the development of A2m amyloidosis under
some clinical conditions.
Finally, interference with the binding of PGs and
GAGs to 2m and/or A2m amyloid fibrils in vivo may
be an attractive therapeutic objective. Kisilevsky et al [57]
demonstrated that low-molecular-weight (135 to 1000)
anionic sulphonate or sulfate compounds substantially
reduce murine splenic AA amyloid progression and in-
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terfere with heparan sulfate–stimulated A fibril aggre-
gation in vitro. Using primary hepatocyte cultures, they
recently reported that a 4-deoxy analog of N-acetylglu-
cosamine is incorporated into heparan sulfate and termi-
nates its elongation [58]. They also demonstrated that
this analog inhibits splenic AA amyloid deposition in an
in vivo model of AA amyloid induction [58]. Recently,
we found that trifluoroethanol at concentrations of up
to 20% (vol/vol) caused fibril extension of heparan-stabi-
lized seeds at a neutral pH, inducing a subtle change in
the tertiary structure of 2m, and stabilizing the fibrils
at a neutral pH [Yamamoto et al; manuscript in prepara-
tion]. Additionally, some GAGs, especially heparan,
dose-dependently enhanced the fibril extension at a neu-
tral pH in the presence of trifluoroethanol (TFE) [Yama-
moto et al; manuscript in preparation]. The experimental
system developed in our laboratory should be useful in
searching for the drugs protecting the interaction of these
molecules.
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